ARK Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$123M	Buy	40,212,769 +2,895,913	+8%	+$11.2M	0.96%	36
2025 Q4	$153M	Buy	37,316,856 +3,771,357	+11%	+$18.7M	1.01%	33
2025 Q3	$164M	Buy	33,545,499 +556,868	+2%	+$2.92M	0.97%	27
2025 Q2	$167M	Sell	32,988,631 -1,826,871	-5%	-$8.97M	1.22%	21
2025 Q1	$184M	Buy	34,815,502 +2,469,104	+8%	+$18M	1.84%	17
2024 Q4	$219M	Sell	32,346,398 -422,788	-1%	-$2.84M	1.82%	16
2024 Q3	$216M	Buy	32,769,186 +4,626,268	+16%	+$33.2M	1.98%	16
2024 Q2	$211M	Buy	28,142,918 +3,555,357	+14%	+$31M	1.87%	17
2024 Q1	$245M	Buy	24,587,561 +3,933,274	+19%	+$43.8M	1.7%	16
2023 Q4	$204M	Buy	20,654,287 +13,777,689	+200%	+$98.2M	1.21%	24
2023 Q3	$52.6M	Buy	6,876,598 +2,138,081	+45%	+$21.3M	0.4%	39
2023 Q2	$35.4M	Buy	4,738,517 +1,161,655	+32%	+$8.13M	0.23%	53
2023 Q1	$23.9M	Buy	3,576,862 +477,372	+15%	+$3.79M	0.16%	64
2022 Q4	$23.9M	Sell	3,099,490 -260,321	-8%	-$2.55M	0.21%	62
2022 Q3	$35.7M	Buy	3,359,811 +627,724	+23%	+$6.36M	0.25%	55
2022 Q2	$16.7M	Sell	2,732,087 -95,076	-3%	-$636K	0.1%	104
2022 Q1	$20.2M	Buy	2,827,163 +595,150	+27%	+$6.33M	0.08%	109
2021 Q4	$38.2M	Sell	2,232,013 -361,823	-14%	-$6.81M	0.12%	103
2021 Q3	$59.7M	Buy	2,593,836 +215,161	+9%	+$6.1M	0.14%	102
2021 Q2	$86.8M	Buy	+2,378,675	New	+$70.4M	0.16%	96